1. Home
  2. SORA vs BEAT Comparison

SORA vs BEAT Comparison

Compare SORA & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Top Win International Limited Ordinary Shares

SORA

Top Win International Limited Ordinary Shares

HOLD

Current Price

$1.90

Market Cap

47.0M

Sector

Industrials

ML Signal

HOLD

Logo Heartbeam Inc.

BEAT

Heartbeam Inc.

HOLD

Current Price

$0.61

Market Cap

53.2M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
SORA
BEAT
Founded
2001
2015
Country
Hong Kong
United States
Employees
7
16
Industry
Other Specialty Stores
Retail: Computer Software & Peripheral Equipment
Sector
Industrials
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
47.0M
53.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SORA
BEAT
Price
$1.90
$0.61
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.63
AVG Volume (30 Days)
5.7K
492.2K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$315.97
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.57
$0.54
52 Week High
$7.51
$4.00

Technical Indicators

Market Signals
Indicator
SORA
BEAT
Relative Strength Index (RSI) 43.30 34.03
Support Level $1.84 $0.54
Resistance Level $2.14 $0.79
Average True Range (ATR) 0.30 0.06
MACD -0.01 -0.00
Stochastic Oscillator 32.94 10.43

Price Performance

Historical Comparison
SORA
BEAT

About SORA Top Win International Limited Ordinary Shares

AsiaStrategy is a wholesaler engaged in trading, distribution, and retail of luxury watches of international brands. The Group sources its luxury watches from Europe, Singapore, Japan, and Hong Kong, then sells the goods to retail sellers and other distributors in the watch industry.

About BEAT Heartbeam Inc.

HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.

Share on Social Networks: